Demographics, underlying malignancies, and medications
Forty patients with biopsy-proven cutaneous irAEs (24 males, 18 females) met the eligibility criteria. Patient demographics, underlying malignancies, and the ICIs administered are summarized in Table 1. The most frequent cancer types were lung cancer (n = 17) and melanoma (n = 12). Other malignancies (n = 13) included Merkel cell carcinoma (n = 1), cutaneous squamous cell carcinoma of the head and neck (n = 3), sebaceous carcinoma of the head and neck (n = 1), esophageal squamous cell carcinoma (n = 2), gastric adenocarcinoma (n = 1), renal cell carcinoma (n = 4), and urothelial carcinoma (n = 1).
Cutaneous irAEs were most commonly associated with the anti–PD-1 antibodies nivolumab (19/42, 45.2%) and pembrolizumab (10/42, 23.8%), followed by combination anti–PD-1 and anti–CTLA-4 therapy with nivolumab and ipilimumab (5/42, 11.9%). The anti–PD-L1 antibodies atezolizumab (4/42, 9.5%) and avelumab (2/42, 4.8%) and anti–CTLA-4 antibody ipilimumab (2/42, 4.8%) were associated with fewer cutaneous irAEs.